Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3541-3546

  Ferreira, Maria José U ^a   Duarte, Noélia ^a   Gyémánt, Nora ^b   Radics, Rita ^b   Cherepnev, Georgy ^c   Varga, Andras ^c   Molnár, Joseph ^b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF SZEGED   (Hungary)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Apoptosis; Euphorbia lagascae; Multidrug resistance; Stilbenes

Indexed keywords

3,5 DIHYDROXY 3',4' DIMETHOXYSTILBENE; 3,5,3' TRIHYDROXY 4' METHOXYSTILBENE; 3,5,3',4' TETRAMETHOXYSTILBENE; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN P; LIPOCORTIN 5; MULTIDRUG RESISTANCE PROTEIN 1; PICEATANNOL; PROPIDIUM IODIDE; RHODAMINE 123; STILBENE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA; MASS SPECTROMETRY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CALCIUM CHANNEL BLOCKERS; CELL LINE, TUMOR; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EUPHORBIA; FLUORESCENT DYES; HUMANS; LYMPHOMA; MICE; P-GLYCOPROTEIN; RHODAMINE 123; SEEDS; STILBENES; VERAPAMIL;

EID: 33750696293     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Roupe KA, Remsberg CM, Yáñez JA and Davies NM: Pharmacometrics of stilbenes: Seguing towards the clinic. Curr Clin Pharm 1: 81-101, 2006.
2. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004.
3. Ferrigni NR, McLaughlin JL, Powell RG and Smith CR Jr: Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 47: 347-352, 1984.
4. Geahlen RL and McLaughlin J: Piceatannol (3,4,3′,5′- tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 165: 241-245, 1989.
5. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA and Burke MD: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778, 2002.
6. Krishna R and Mayer LD: Modulation of P-glycoprotein (P-GP) mediated multidrug resistance (MDR) using chemosensitizers: Recent advances in the design of selective MDR modulators. Curr Med Chem - Anti-Cancer Agents 1: 163-174, 2001.
7. Avendaño C and Menéndez JC: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 9: 159-193, 2002.
8. Cardona ML, Fernandez MI, Garcia M and Pedro J: Synthesis of natural polyhydroxystilbenes. Tetrahedron 42: 2725-2730, 1986.
9. Gill MT, Bajaj R, Chang C, Nichols D and McLaughlin J: 3,3′,5′-tri-O-methylpiceatannol and 4,3′,5′-tri-O- methylpiceatannol: improvements over piceatannol in bioactivity. J Nat Prod 50: 36-40, 1987.
10. Talvitie A, Mannila E and Kolehmainen E: Synthesis of some biologically active compounds from stilbenes isolated from the bark of Picea abies. Liebigs Ann Chem 399-401, 1992.
11. Kim S, Ko H, Park J, Jung S, Lee S and Chun Y: Design, synthesis and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem 45: 160-164, 2002.
12. Thakkar K, Geahlen R and Cushman M: Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J Med Chem 36: 2950-2955, 1993.
13. Teguo P, Decendit A, Krisa S, Deffieux G, Vercauteren J and Mérillon J: The accumulation of stilbene glycosides in Vitis vinifera cell suspension cultures. J Nat Prod 59: 1189-1191, 1996.
14. Cornwell MM, Pastan I and Gottesmann MM: Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170, 1987.
15. Weaver JL, Szabo G, Pine PS, Gottesman MM, Goldenberg S and Aszalos A: The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multidrug transporter. Int J Cancer 54: 456-461, 1993.
16. Kessel D: Explorating multidrug resistance using Rhodamine 123. Cancer Commun 1: 145-149, 1989.
17. Koopmann G, Rentelinger CP, Kuijten GA, Koehnen RM, Pals ST and Van OMH: Annexin V flow cytometric detection of phosphatidyl-serine expression on B cells undergoing apoptosis. Blood 84: 1115-1120, 1994.
18. Seelig A: A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251: 252-2261, 1998.
19. Wiese M and Pajeva IK: Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 8: 685-713, 2001.